Anthropic Revenue Run Rate Hits $65 Billion as IPO Plans Accelerate 
S&P 500 Retreats From Record High as AI Stocks Slide, Retail Sales Disappoint 
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Nvidia’s $500 Billion AI Infrastructure Push Wins Morgan Stanley Support 
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Yen Edges Higher as Weak US Data Dampens Fed Rate Hike Expectations 
Foreign U.S. Treasury Holdings Fall as Japan, UK and China Cut Positions 
BofA Sees Micron EPS Topping $230 by 2030, Backs Major Stock Upside 
Asian Currencies Edge Higher as Soft US Inflation Weighs on Dollar 
Sun Pharma Wins U.S. Appeal in Pfizer Lipitor Antitrust Case 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Add as a preferred source on Google
SK Bioscience has applied for conditional approval for the use of SKY Covione, a COVID-19 vaccine, with the European Medicines Agency (EMA).
SKY Covione, developed jointly by the biotech affiliate of SK Group and the Institute for Protein Design (IPD) at the University of Washington, is a synthetic vaccine considered safer than those originating from bacterial cultures.
The Bill & Melinda Gates Foundation provided funding for the product development.
According to Phase 3 clinical studies, the vaccine is significantly more immunogenic than the control vaccination Vaxzeria from AstraZeneca, according to SK Bioscience.
Extensive research in Phase 1 therapeutic trials showed that SKY Covione also induced a potent immune response against BA.1, of the Omicron variant family, when provided with booster shots.
The SK affiliate anticipates that the product will have a competitive advantage in the international market, which requires a consistent and stable supply of vaccines in the upcoming months.
Once it is added to the World Health Organization (WHO) Emergency Use List, it will be distributed to the global market through the COVID-19 Vaccines Global Access (COVAX) project, a global program created to enable equal access to COVID-19 vaccines.
According to data from the Korea Customs Service, Korea imported $2.35 billion worth of vaccines last year, a seven-fold rise from $340 million the year before.
